文献速递心力衰竭与心肌病

恩格列净或安慰剂长期随机治疗在心力衰竭患者中的盲法撤药研究

Blinded Withdrawal of Long-Term Randomized Treatment With Empagliflozin or Placebo in Patients With Heart Failure.
PubMed 文献 · Circulation · 2023-08-24

本研究基于EMPEROR-Reduced和EMPEROR-Preserved试验,对6799例心力衰竭患者进行盲法撤药,其中3981例完成约30天撤药后评估。结果显示,恩格列净治疗期间心血管死亡或心衰住院风险低于安慰剂,撤药后恩格列净组风险迅速增加,且KCCQ临床总结评分下降,多项生理指标反向变化,表明恩格列净的获益在长期治疗后持续存在但撤药后迅速消失。

要点

  • 恩格列净治疗期间心血管死亡或心衰住院风险低于安慰剂(HR 0.76)。
  • 撤药约30天后,恩格列净组风险增加(HR 1.75),安慰剂组无显著变化。
  • 撤药后KCCQ临床总结评分下降,多项生理指标反向变化。

核心结论

  • 恩格列净在心力衰竭患者中具有持续获益,但撤药后迅速消失。

研究设计与样本

  • 基于EMPEROR-Reduced和EMPEROR-Preserved随机双盲试验,患者随机接受安慰剂或恩格列净10 mg/日,中位治疗时间分别为16和26个月。
  • 试验结束时,6799例患者(安慰剂3381例,恩格列净3418例)前瞻性盲法撤药,其中3981例(安慰剂2020例,恩格列净1961例)在撤药约30天后进行预设的面对面评估。

主要发现

  • 从关闭期开始90天至双盲治疗结束,恩格列净组心血管死亡或心衰住院年化风险为10.7(95%CI 9.0-12.6)事件/100患者年,安慰剂组为13.5(95%CI 11.5-15.6),HR 0.76(95%CI 0.60-0.96)。
  • 撤药约30天后,恩格列净组心血管死亡或心衰住院年化风险为17.0(95%CI 12.6-22.1)事件/100患者年,安慰剂组为14.1(95%CI 10.1-18.8);恩格列净组风险变化HR 1.75(95%CI 1.20-2.54),P=0.0034;安慰剂组变化无统计学意义(HR 1.12,95%CI 0.76-1.66);时间期-by-治疗交互P=0.068。
  • 撤药后,恩格列净组KCCQ临床总结评分下降1.6±0.4,与安慰剂组相比P<0.0001。
  • 撤药后,恩格列净组空腹血糖、体重、收缩压、估算肾小球滤过率、N末端B型利钠肽原、尿酸和血清碳酸氢盐升高,血红蛋白和血细胞比容降低(所有P<0.01)。
  • 这些生理和实验室变化与同一队列患者试验开始时(约1-3年前)启动治疗时的效应相反。

临床怎么用

  • 恩格列净治疗心力衰竭的获益在长期治疗后仍持续,不应随意撤药。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: It is not known whether the benefits of sodium-glucose cotransporter 2 inhibitors in heart failure persist after years of therapy. METHODS: In the EMPEROR-Reduced (Empagliflozin Outcome Trials in Chronic Heart Failure With Reduced Ejection Fraction) and EMPEROR-Preserved (Empagliflozin Outcome Trials in Chronic Heart Failure With Preserved Ejection Fraction) trials, patients with heart failure were randomly assigned (double-blind) to placebo or empagliflozin 10 mg/day for a median of 16 and 26 months, respectively. At the end of the trials, 6799 patients (placebo 3381, empagliflozin 3418) were prospectively withdrawn from treatment in a blinded manner, and, of these, 3981 patients (placebo 2020, empagliflozin 1961) underwent prespecified in-person assessments after ≈30 days off treatment. RESULTS: From 90 days from the start of closeout to the end of double-blind treatment, the annualized risk of cardiovascular death or hospitalization for heart failure was lower in empagliflozin-treated patients than in placebo-treated patients (10.7 [95% CI, 9.0-12.6] versus 13.5 [95% CI, 11.5-15.6] events per 100 patient-years, respectively; hazard ratio 0.76 [95% CI, 0.60-0.96]). When the study drugs were withdrawn for ≈30 days, the annualized risk of cardiovascular death or hospitalization for heart failure increased in patients withdrawn from empagliflozin but not in those withdrawn from placebo (17.0 [95% CI, 12.6-22.1] versus 14.1 [95% CI, 10.1-18.8] events per 100 patient-years for empagliflozin and placebo, respectively). The hazard ratio for the change in risk in the patients withdrawn from empagliflozin was 1.75 (95% CI, 1.20-2.54), P=0.0034, whereas the change in the risk in patients withdrawn from placebo was not significant (hazard ratio 1.12 [95% CI, 0.76-1.66]); time period-by-treatment interaction, P=0.068. After withdrawal, the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score declined by 1.6±0.4 in patients withdrawn from empagliflozin versus placebo (P<0.0001). Furthermore, withdrawal of empagliflozin was accompanied by increases in fasting glucose, body weight, systolic blood pressure, estimated glomerular filtration rate, N-terminal pro-hormone B-type natriuretic peptide, uric acid, and serum bicarbonate and decreases in hemoglobin and hematocrit (all P<0.01). These physiological and laboratory changes were the inverse of the effects of the drug seen at the start of the trials during the initiation of treatment (≈1-3 years earlier) in the same cohort of patients. CONCLUSIONS: These observations demonstrate a persistent effect of empagliflozin in patients with heart failure even after years of treatment, which dissipated rapidly after withdrawal of the drug. REGISTRATION: URL: https://www. CLINICALTRIALS: gov; Unique identifiers: NCT03057977 and NCT03057951.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Packer, Butler, Zeller, et al. Blinded Withdrawal of Long-Term Randomized Treatment With Empagliflozin or Placebo in Patients With Heart Failure. Circulation. 2023. PMID: 37621153. doi:10.1161/CIRCULATIONAHA.123.065748

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。